Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now

NMOSD Drug Pipeline: IL-6, Complement & FcRn — PatSnap Eureka

NMOSD Drug Pipeline: IL-6, Complement & FcRn — PatSnap Eureka
NMOSD Drug Pipeline Intelligence

NMOSD Drug Pipeline: IL-6, Complement & FcRn Inhibitor Approaches Beyond Eculizumab

Neuromyelitis optica spectrum disorder has moved decisively beyond first-generation complement inhibition. Explore the patent and clinical landscape spanning anti-CD19 B cell depletion, IL-6 pathway blockade, C1-esterase inhibition, FcRn-mediated IgG clearance, and AQP4-targeted tolerance strategies.

NMOSD Therapeutic Modalities by Patent Activity: Anti-C5 Complement (Alexion, RA Pharma), Anti-CD19 B Cell (Viela Bio, 9+ jurisdictions), C1-INH (Shire ViroPharma), FcRn/Fc Multimer (CSL Behring), AQP4-Blocking (U. Colorado), IL-6 Pathway (Tocilizumab/Satralizumab), RGMa Neuroprotection (Osaka U.) Overview of NMOSD therapeutic modalities ranked by patent activity and clinical evidence stage, derived from PatSnap Eureka patent and literature analysis. Anti-C5 complement inhibition and anti-CD19 B cell depletion represent the most densely patented segments. NMOSD PATENT ACTIVITY BY MODALITY Anti-C5 Highest Anti-CD19 9+ Jurisdictions C1-INH EP Active FcRn/Fc WO + CA AQP4-Block EP/CA/HK IL-6 Path Clinical RGMa EP Commercial Clinical Evidence Academic
9+
Jurisdictions for inebilizumab patent prosecution
99
Clinical centres in inebilizumab NMOSD trial
24
Countries in anti-CD19 NMOSD clinical cohort
30%
5-year NMO mortality cited in Alexion filings
Disease & Target Overview

NMOSD: An Astrocytopathic Disorder Driven by AQP4-IgG

Neuromyelitis optica spectrum disorder (NMOSD) is consistently framed in retrieved patent and literature results as an astrocytopathic rather than purely demyelinating disorder. The primary antigenic target is aquaporin-4 (AQP4), a water channel protein expressed on astrocytic endfeet. Viela Bio patent filings across multiple jurisdictions describe NMOSD as "a severe, autoimmune, inflammatory, central nervous system disease with a prevalence of 0.5–4.4/100,000," noting that AQP4-IgG seropositivity is the central pathogenic and diagnostic feature.

Pathogenic AQP4-IgG binding to astrocytes triggers complement cascade activation, culminating in membrane attack complex (MAC) formation and tissue destruction. PatSnap's life sciences intelligence platform captures this mechanistic landscape across thousands of patent families spanning complement inhibition, B cell depletion, IL-6 blockade, and novel FcRn-based clearance strategies.

The World Health Organization classifies NMOSD as a rare, severe neurological condition. Beyond complement component 5 (C5), retrieved results highlight IL-6 receptor as a cytokine driver of AQP4-IgG–producing plasmablasts, CD19 and B cells as cellular mediators, repulsive guidance molecule A (RGMa) as a novel acute-phase target, and IgG Fc multimers as a mechanism for clearing pathogenic AQP4-IgG via FcRn competition.

0.5–4.4
Prevalence per 100,000 (Viela Bio filings)
50%
Patients sustaining permanent severe disability
30%
5-year NMO mortality (Alexion patent filings)
9
Distinct therapeutic modalities identified in this dataset
Key Targets in Retrieved Results
  • AQP4 — primary autoantigen
  • Complement C5 — terminal pathway node
  • Complement C1 — upstream classical pathway
  • IL-6 receptor — plasmablast driver
  • CD19 / B cells — pathogenic antibody production
  • FcRn — IgG catabolism mechanism
  • RGMa — acute neuroprotection target
Therapeutic Modalities

Nine Distinct Approaches Identified in the NMOSD Pipeline

From complement inhibition and B cell depletion to FcRn-mediated IgG clearance and antigen-specific tolerance induction, the NMOSD pipeline spans multiple mechanistic classes with varying evidence stages.

Complement Inhibition · Anti-C5

Anti-C5 Antibodies (Eculizumab & Next-Generation)

Multiple Alexion Pharmaceuticals patents across WO, CA, MX, CO, JP, and CN jurisdictions describe methods for treating NMOSD using anti-C5 antibodies. These agents reduce the rate at which C5 is cleaved into C5a (anaphylatoxin) and C5b (MAC-initiating fragment), blocking downstream astrocyte destruction. A 2025 Alexion WO biomarker patent discloses serum GFAP and NfL as pharmacodynamic readout proteins for monitoring C5 inhibitor treatment response.

✓ Clinical — open-label & placebo-controlled data referenced
B Cell Depletion · Anti-CD19

Inebilizumab (VIB551) — Anti-CD19 Afucosylated IgG1κ

The largest single-assignee patent cluster in this dataset comes from Viela Bio, with filings across WO, US, CA, AU, BR, MX, JP, IL, and SG. Inebilizumab's afucosylation engineering enhances ADCC activity, enabling deeper B cell depletion including plasmablasts and plasma cells expressing CD19 but lacking CD20 — a key differentiation from rituximab. Clinical trial data across 99 centres and 24 countries is referenced in filings.

✓ Clinical — 99 centres, 24 countries trial referenced
Complement Inhibition · C1

C1-Esterase Inhibitor (C1-INH) — Acute Rescue Paradigm

Two patent families from Shire ViroPharma Incorporated and ViroPharma Holdings Limited describe C1-INH (plasma-derived CINRYZE and recombinant forms) for NMO/NMOSD. The mechanism blocks the classical complement pathway at its initiation step, upstream of C3 and C5 cleavage. Filings specify administration at the onset of an active CNS attack — positioning C1-INH as acute rescue rather than long-term prophylaxis. EP active status indicates granted European protection.

Preclinical/Early Translational · EP Active
FcRn Competition · IgG Clearance

Recombinant IgG Fc Multimers (CSL Behring)

CSL Behring Lengnau AG holds WO and CA patents on recombinant IgG Fc multimers for NMO. High-dose Fc multimers compete for FcRn (neonatal Fc receptor) binding, accelerating catabolism of circulating pathogenic AQP4-IgG. This approach is positioned as a more targeted, manufacturing-efficient alternative to polyclonal IVIg (1–2 g/kg/dose) for NMO, mechanistically orthogonal to complement inhibition or B cell depletion.

Preclinical/Early · WO + CA Filed
IL-6 Pathway · Cytokine Blockade

Tocilizumab & Satralizumab — IL-6 Receptor Inhibition

Tocilizumab is referenced in a longitudinal clinical study from Tianjin Medical University General Hospital examining retinal damage in 50 AQP4-seropositive NMOSD patients. Annual macular ganglion cell complex thinning rates were measured under tocilizumab, rituximab, and azathioprine using optical coherence tomography. Satralizumab appears in a Viela Bio JP patent as a comparator therapy alongside eculizumab and inebilizumab.

✓ Clinical longitudinal OCT study referenced
AQP4 Targeting · Effector-Null

AQP4-Blocking Antibodies (University of Colorado)

The Regents of the University of Colorado filed patents in EP, CA, and HK claiming antibodies that bind AQP4 but lack complement-activating effector functions — achieved via Fc mutations L234A/L235A or K322A, or through IgG4 formats. The rationale: blocking pathogenic AQP4-IgG from binding its target without triggering further complement activation. This NIH-funded academic approach decouples AQP4 occupancy from immune effector recruitment.

Preclinical · NIH-funded academic origin
AQP4 Targeting · Tolerance Induction

AQP4 Peptide Immunotherapy (Imcyse SA)

Imcyse SA (Belgium) holds pending AU and IN patents on immunogenic peptides derived from the AQP4 extracellular domain designed to generate cytolytic CD4+ T cells or NKT cells that selectively eliminate AQP4-presenting cells. Redox motif-containing peptides redirect T cell responses toward antigen-specific tolerance. Retrieved text notes that combination with prior antibody depletion therapy (e.g., rituximab or plasmapheresis) is preferred to reduce circulating AQP4-IgG titers first.

Preclinical · Sequential combination claimed
Neuroprotection · Acute Phase

RGMa Inhibition (Osaka University)

Osaka University holds an EP patent on repulsive guidance molecule A (RGMa) inhibiting substances for preventing or treating acute-phase NMO and its associated pain symptoms. This is the only retrieved filing addressing a non-immunological, neuroprotective mechanism specifically in acute NMO — representing a potential acute-phase add-on complementary to longer-term immunosuppressive approaches.

Preclinical · EP Filed 2022
PatSnap Eureka

Map the Full NMOSD Patent Landscape

Search across all assignees, jurisdictions, and filing dates for every NMOSD modality.

Explore NMOSD Patents in Eureka
Pipeline Analytics

NMOSD Patent Activity & Clinical Evidence Signals

Data visualisations derived from PatSnap Eureka patent and literature analysis across the NMOSD therapeutic landscape.

Patent Families by Therapeutic Modality

Anti-C5 complement inhibition and anti-CD19 B cell depletion dominate the NMOSD patent landscape by volume of families and jurisdictions.

NMOSD Patent Families by Modality: Anti-C5/Complement (Alexion, RA Pharma) Highest; Anti-CD19 9+ Jurisdictions; C1-INH 2 Families EP Active; FcRn/Fc Multimer 2 Families WO+CA; AQP4-Blocking EP/CA/HK; IL-6 Pathway Clinical; RGMa EP Only Horizontal bar chart comparing NMOSD patent activity across seven therapeutic modalities based on PatSnap Eureka patent analysis. Anti-C5 complement inhibition leads with the most patent families, followed by anti-CD19 B cell depletion with prosecution across 9+ jurisdictions. Anti-C5 Alexion + RA Pharma Anti-CD19 9+ Jurisdictions C1-INH EP Active FcRn/Fc WO + CA AQP4-Block EP / CA / HK IL-6 Path Clinical Evidence RGMa EP Only

Development Stage Distribution

Three modalities have clinical evidence referenced in retrieved filings; four remain at preclinical or early translational stage based on filing content.

NMOSD Modality Development Stage: Clinical Evidence 3 modalities (Anti-C5, Anti-CD19, IL-6); Preclinical/Early 4 modalities (C1-INH, FcRn, AQP4-Blocking, RGMa/Peptide) Donut chart showing that 3 of 7 NMOSD therapeutic modalities identified in this PatSnap Eureka dataset have clinical evidence referenced in patent filings or literature, while 4 remain at preclinical or early translational stage. 7 Modalities Clinical Evidence 3 modalities · 43% Anti-C5, Anti-CD19, IL-6 Preclinical/Early 4 modalities · 57% C1-INH, FcRn, AQP4, RGMa

Run real-time patent searches across all NMOSD targets and assignees in PatSnap Eureka.

Analyse NMOSD Patent Data Now
Assignee & Author Landscape

Key Patent Filers in the NMOSD Innovation Space

Commercial patent filers dominate this dataset, with academic contributions appearing primarily through literature and institutional patents.

🔒
Unlock the Full Assignee & Filing Analysis
Access complete patent family details, jurisdiction status, filing dates, and competitive IP mapping for all NMOSD assignees in PatSnap Eureka.
Jurisdiction status Filing chronology Claim scope + more
Access Full Patent Data →

Track NMOSD IP Prosecution in Real Time

Monitor assignee activity, jurisdiction grants, and new filings with PatSnap Analytics.

Start IP Monitoring
Clinical & Translational Signals

Biomarker-Guided Treatment Selection Is Emerging Across Modalities

Across Viela Bio and Alexion patent filings, serum GFAP and neurofilament light chain (sNfL) appear as patient stratification and treatment monitoring tools with specific concentration thresholds disclosed. Viela Bio's AU filing discloses a GFAP threshold in the approximately 168–181 pg/mL range. Inebilizumab is indicated for patients with elevated sNfL and/or elevated serum GFAP as markers of active disease, regardless of whether a clinical attack has occurred — potentially enabling pre-attack intervention.

The PatSnap life sciences intelligence platform indexes these biomarker disclosures alongside clinical trial references. The Alexion 2025 WO biomarker patent discloses serum GFAP and NfL data collected from eculizumab-treated patients in placebo-controlled settings, signalling a completed or ongoing controlled clinical study with biomarker substudies.

A University College London study (2012) documented that serum neurofilament heavy chain (NfH) levels are highest in NMO versus MS and chronic relapsing inflammatory optic neuritis — providing the clinical foundation for biomarker-guided trial design. The National Institutes of Health has supported academic AQP4 research including the University of Colorado effector-null antibody programme.

The Tianjin Medical University General Hospital paper provides prospective OCT data in 50 AQP4-seropositive NMOSD patients, reporting annual macular ganglion cell complex thinning rates under tocilizumab, rituximab, and azathioprine — a clinical comparator study with quantified structural outcomes. The European Medicines Agency provides regulatory guidance on rare neurological disease trials relevant to this pipeline.

Clinical Evidence Retrieved
Inebilizumab RCT
99 centres · 24 countries · placebo-controlled
Eculizumab Open-Label
14 AQP4-IgG+ patients · reduced relapse frequency
Tocilizumab OCT Study
50 AQP4+ patients · macular GCC thinning rates
UCL NfH Biomarker Study
NMO vs. MS vs. CRION · NfH highest in NMO
GFAP Threshold
168–181
pg/mL range disclosed in Viela Bio AU filing for patient stratification
Strategic Implications

IP Strategy & Competitive Positioning in NMOSD

Derived from patent filing patterns, assignee activity, and clinical evidence signals retrieved via PatSnap Eureka.

🧬

Complement Space Approaching IP Maturity

The complement pathway remains the most densely patented NMOSD intervention space in this dataset, with Alexion holding a multi-jurisdictional portfolio spanning both first-generation (eculizumab) and next-generation antibody formats plus biomarker IP. New entrants must differentiate on format (e.g., peptides, tissue penetration) or delivery route rather than target novelty.

🏢

AstraZeneca Holds Dual NMOSD Franchises

AstraZeneca's acquisition of Viela Bio positions the company to hold overlapping complement (Alexion) and B cell (Viela) NMOSD franchises simultaneously, creating a potential combination therapy bundling strategy. Viela Bio's anti-CD19 portfolio is the largest NMOSD-specific commercial patent cluster in this dataset, with active prosecution in 9+ jurisdictions and clinical proof-of-concept data embedded in the filings.

🔒
Unlock Full Strategic Analysis
Access the complete competitive intelligence framework including FcRn positioning, biomarker strategy signals, and AQP4 tolerance induction outlook via PatSnap Eureka.
FcRn competitive positioning Biomarker IP strategy + more
Unlock Full Strategy Report →
Combination Approaches & Emerging Directions

Sequential & Multi-Modality Strategies in NMOSD

Retrieved results signal several explicit combination strategies and emerging paradigms across assignees.

Sequential Combination

Antibody Depletion + AQP4 Peptide Tolerance (Imcyse SA)

Multiple AU patent filings from Imcyse SA specify that antibody depletion therapy (e.g., rituximab or plasmapheresis) should precede AQP4 peptide immunotherapy to reduce circulating AQP4-IgG titers before installing antigen-specific tolerance. This sequential combination is explicitly claimed in the filings.

Explicitly claimed sequential strategy
Biomarker-Guided

Anti-CD19 + Biomarker Stratification (Viela Bio)

Retrieved filings describe a biomarker-guided concept in which sNfL and/or serum GFAP threshold measurements are used to identify patients who would benefit from inebilizumab even in the absence of a clinical attack — potentially enabling pre-attack intervention before irreversible tissue damage occurs.

Pre-attack intervention paradigm
Pharmacodynamic Monitoring

C5 Inhibitor + GFAP/NfL Monitoring (Alexion 2025)

The 2025 Alexion WO biomarker patent signals an emerging paradigm of pharmacodynamic monitoring combined with complement inhibition, potentially enabling dose optimization or early identification of non-responders in clinical practice.

Dose optimisation signal
Multi-Modality Landscape

Satralizumab, Eculizumab & Inebilizumab Co-Referenced

A Viela Bio Japanese filing (2023) lists satralizumab (anti-IL-6R), eculizumab, ubltituximab (anti-CD20), ravulizumab (long-acting anti-C5), rituximab, azathioprine, and mycophenolate mofetil as treatment options — suggesting the clinical community is moving toward a multi-modality landscape where complement inhibition, IL-6 blockade, and B cell depletion may be selected or sequenced based on patient profile. Learn more about competitive landscape analytics via PatSnap.

Multi-modality sequencing emerging
Frequently asked questions

NMOSD Drug Pipeline — Key Questions Answered

Still have questions? Let PatSnap Eureka answer them for you.

Ask Eureka About NMOSD Patents
PatSnap Eureka

Accelerate Your NMOSD Drug Pipeline Research

Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search the full NMOSD patent and literature landscape — from complement inhibitors to FcRn approaches — in a single AI-powered platform.

References

  1. Methods of Treating Neuromyelitis Optica Spectrum Disorder — Viela Bio, Inc., 2022, WO [Patent]
  2. Use of an Anti-CD19 Antibody to Treat Autoimmune Disease — Viela Bio, Inc., 2022, US [Patent]
  3. Use of an Anti-CD19 Antibody to Treat Autoimmune Disease — Viela Bio, Inc., 2021, AU [Patent]
  4. Anti-C5 Antibody for the Treatment of Neuromyelitis Optica Spectrum Disorder — Alexion Pharmaceuticals, Inc., 2021, WO [Patent]
  5. Biomarkers for Monitoring Effective Treatment of NMOSD with Complement Component C5 Inhibitors — Alexion Pharmaceuticals, Inc., 2025, WO [Patent]
  6. Compositions and Methods for the Treatment of Neuromyelitis Optica — Alexion Pharmaceuticals, Inc., 2020, US [Patent]
  7. Compositions and Methods Useful for the Treatment of Neuromyelitis Optica Spectrum Disorders — Shire ViroPharma Incorporated, 2016, EP [Patent]
  8. Compositions and Methods Useful for the Treatment of Neuromyelitis Optica Spectrum Disorders — ViroPharma Holdings Limited, 2015, WO [Patent]
  9. Recombinant IgG Fc Multimers for the Treatment of Neuromyelitis Optica — CSL Behring Lengnau AG, 2019, WO [Patent]
  10. Zilucoplan as a Deep-Tissue-Penetrating C5 Inhibitor — RA Pharmaceuticals, Inc., 2021, CN [Patent]
  11. Compositions and Methods for the Treatment of Neuromyelitis Optica — The Regents of the University of Colorado, 2022, CA [Patent]
  12. Peptides and Methods for the Treatment of Neuromyelitis Optica — Imcyse SA, 2023, AU [Patent]
  13. Agent for Preventing or Treating Acute-Phase Neuromyelitis Optica — Osaka University, 2022, EP [Patent]
  14. Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder — Tianjin Medical University General Hospital, 2021 [Paper]
  15. World Health Organization — Rare Neurological Diseases
  16. National Institutes of Health — Neurological Research Funding
  17. European Medicines Agency — Rare Disease Regulatory Guidance

All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.

Ask PatSnap Eureka
Ask PatSnap Eureka
AI innovation intelligence · always on
Ask anything about the NMOSD drug pipeline.
PatSnap Eureka searches patents and research to answer instantly.
Try asking
Powered by PatSnap Eureka